UMMS Affiliation

Department of Medicine, Division of Cardiovascular Medicine

Publication Date

2020-12-23

Document Type

Article Preprint

Disciplines

Cardiovascular Diseases | Cardiovascular System | Cell Biology | Cellular and Molecular Physiology | Hemic and Immune Systems | Immunology and Infectious Disease | Infectious Disease | Microbiology | Virus Diseases

Abstract

Coronavirus disease-2019 (COVID-19) caused by SARS-CoV-2 is an ongoing viral pandemic marked by increased risk of thrombotic events. However, the role of platelets in the elevated observed thrombotic risk in COVID-19 and utility of anti-platelet agents in attenuating thrombosis is unknown. We aimed to determine if human platelets express the known SARS-CoV-2 receptor-protease axis on their cell surface and assess whether the anti-platelet effect of aspirin may mitigate risk of myocardial infarction (MI), cerebrovascular accident (CVA), and venous thromboembolism (VTE) in COVID-19. Expression of ACE2 and TMPRSS2 on human platelets were detected by immunoblotting and confirmed by confocal microscopy. We evaluated 22,072 symptomatic patients tested for COVID-19. Propensity-matched analyses were performed to determine if treatment with aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) affected thrombotic outcomes in COVID-19. Neither aspirin nor NSAIDs affected mortality in COVID-19. However, both aspirin and NSAID therapies were associated with increased risk of the combined thrombotic endpoint of (MI), (CVA), and (VTE). Thus, while platelets clearly express ACE2-TMPRSS2 receptor-protease axis for SARS-CoV-2 infection, aspirin does not prevent thrombosis and death in COVID-19. The mechanisms of thrombosis in COVID-19, therefore, appears distinct and the role of platelets as direct mediators of SARS-CoV-2-mediated thrombosis warrants further investigation.

Keywords

Platelets, SARS-CoV-2, COVID-19, Thrombosis, ACE2, TMPRSS2

Rights and Permissions

This work is licensed under a CC BY 4.0 License.

DOI of Published Version

10.21203/rs.3.rs-119031/v1

Source

Sahai A, Bhandari R, Koupenova M, Freedman J, Godwin M, McIntyre T, Chung M, Iskandar JP, Kamran H, Aggarwal A, Kalra A, Bartholomew J, McCrae K, Elbadawi A, Svensson L, Kapadia S, Hariri E, Cameron S. SARS-CoV-2 Receptors are Expressed on Human Platelets and the Effect of Aspirin on Clinical Outcomes in COVID-19 Patients. Res Sq [Preprint]. 2020 Dec 23:rs.3.rs-119031. doi: 10.21203/rs.3.rs-119031/v1. PMID: 33398263; PMCID: PMC7781327. Link to preprint on Research Square

Journal/Book/Conference Title

Research square

Comments

This article is a preprint. Preprints are preliminary reports of work that have not been certified by peer review.

Full author list omitted for brevity. For the full list of authors, see article.

Related Resources

Link to preprint in PubMed

PubMed ID

33398263

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

COinS